Actively Recruiting
Phase 1 Study to Evaluate Safety and How the Body Processes PF-07328948 in Adults With Normal or Reduced Kidney Function
Led by Pfizer · Updated on 2026-05-12
28
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying how the body processes the medicine PF-07328948 and how safe it is for adults with varying kidney function. The study includes adults aged 18 to 80 with normal or moderately to severely reduced kidney function, with specific body mass index and weight requirements. This research aims to understand how kidney function affects the medicines behavior in the body, helping to guide safe use in people with kidney issues. All participants will take a single oral dose of PF-07328948 as one tablet. The study has three groups based on kidney function those with normal kidneys, moderate impairment, and severe impairment. Each participant will receive the same dose. Participants will stay in a clinical research unit for about six days to take the medicine and undergo safety checks. Participants will be involved for up to 64 days, including screening, the inpatient stay, and a follow-up call. Researchers will collect blood samples at multiple time points after dosing to measure how much of the drug is unbound in the plasma. Monitoring for any side effects will continue up to 36 days after dosing to assess safety and tolerability.
CONDITIONS
Brief Title
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
